Clinical trial
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory…
NCT00144963 · Acrotech Biopharma Inc., Industry · Completed
Key facts
| NCT number | NCT00144963 |
|---|---|
| Title | Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia |
| Official title | Phase I-II Study of Liposomal Vincristine (VSLI) and Dexamethasone in Relapsed or Refractory Acute Lymphoblastic Leukemia |
| Lead sponsor | Acrotech Biopharma Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia |
| Intervention type | Drug |
| Interventions | Vincristine Sulfate Liposomes Injection, Dexamethasone |
| Enrollment | 36 |
| Start date | Jul 1, 2002 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 5, 2005 |
| Last update posted | Dec 12, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: